DiamiR LLC (DiamiR) is a medical device company. It carries out the development and commercialization of technology based on the analysis of brain-enriched microRNA biomarkers in blood plasma to be used for screening, and early and differential diagnosis. The company also offers microRNAs which are a class of small non-coding regulatory RNA molecules which modulate target gene expression and protein production. DiamiR offers a universal screening test comprised of organ-enriched microRNA panels which could be used to detect the presence of pathology in a particular organ or organ system. The company develops programs for neurodegenerative diseases, healthy aging and neurodevelopment disease. It has collaborations with academia, medical centers, disease foundations and industry. DiamiR is headquartered in Monmouth Junction, New Jersey, the US.
This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.
The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.
Scope:
The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
The report analyzes all pipeline products in development for the company DiamiR LLC
The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
The report provides detailed description of products in development, technical specification and functions
The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.
Reasons to Buy:
Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
To formulate effective Research & Development strategies
Develop market-entry and market expansion strategies
Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note:Some sections may be missing if data is unavailable for the company
DiamiR LLC Company Overview
DiamiR LLC Company Snapshot
DiamiR LLC Pipeline Products and Ongoing Clinical Trials Overview
Mdx Test - Mild Cognitive Impairment Product Overview
Universal Screening Test
Universal Screening Test Product Overview
DiamiR LLC - Key Competitors
DiamiR LLC - Key Employees
DiamiR LLC - Locations And Subsidiaries
Head Office
Recent Developments
DiamiR LLC, Recent Developments
Oct 02, 2023: DiamiR Biosciences Announces Poster Presentation at 52nd Annual Meeting of Child Neurology Society
Jul 05, 2023: DiamiR Biosciences Partners with JADBio to Utilize Machine Learning in Assay Development
Jun 28, 2023: DiamiR Biosciences Announces Publication of Analytical Validation Data for its microRNA Testing Platform
Nov 28, 2022: DiamiR Biosciences Announces Poster Presentation at the Clinical Trials on Alzheimers Disease 2022 Annual Meeting
Feb 11, 2021: DiamiR receives USPTO notice of allowance for key patent covering the use of microRNA biomarkers from bodily fluids for diagnosis and monitoring of Rett Syndrome and other neurodevelopmental diseases
Oct 05, 2020: DiamiR announces oral presentation at 21st International Conference on Alzheimer's Drug Discovery
Oct 01, 2020: DiamiR awarded $3.86M in two grants from the NIH
May 27, 2020: DiamiR receives USPTO notice of allowance for key patent covering the use of circulating brain-enriched microRNA biomarkers for monitoring of brain aging; provides update on its patent portfolio
Nov 20, 2019: DiamiR receives award from Alzheimer's Drug Discovery Foundation to accelerate development of microRNA biomarkers for Alzheimer's Disease
Sep 16, 2019: DiamiR announces additional $345,000 funding from the NIH for Development of CogniMIR